Three UCLA hESC lines have been accepted into the NIH Human Embryonic Stem Cell Registry
Three human embryonic stem cell lines created by researchers at the UCLA Broad Stem Cell Research Center have been accepted into the National Institutes of Health (NIH) Human Embryonic Stem Cell Registry, allowing them to be used in federally funded research projects and increasing the diversity of cell lines available for study.
The addition of the three human embryonic stem cells lines to the registry brings the total number of lines available for federal funding to 64, NIH officials said. Another 100 lines are pending approval. UCLA is one of only nine institutions in the world with stem cell lines admitted to the NIH registry.
The lines were developed by Amander Clark, an assistant professor of molecular, cell and developmental biology. Clark collaborated on the project with Nissim Benvenisty, co-director of the International Stem Cell Research Institute at Cedars Sinai Medical Center.
Dr. Owen Witte, director of the UCLA Broad Stem Cell Research Center, said the development of the three lines reflects the quality of work done by researchers at the stem cell center.
“These stem cell lines are very well characterized. We know their precise passage history, chromosome content and stability,” Witte said. “Pluripotent stem cells have the potential to play a vital role in developing effective therapies. Developing new human embryonic stem cell lines is a crucial field of research, and we’re gratified that our scientists were able to accomplish this important feat in a relatively short period of time.”